Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

NCT05465954 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

High Grade Astrocytic Tumor
Recurrent Glioblastoma, IDH-Wildtype
Recurrent Gliosarcoma

Interventions

PROCEDURE: Biospecimen Collection
BIOLOGICAL: Efineptakin alfa
BIOLOGICAL: Pembrolizumab
PROCEDURE: Biopsy

Sponsor

Mayo Clinic

Collaborators

[object Object]
[object Object]
[object Object]